Answers are grounded in this paper and cite their sources.
Our prospective data confirm that anti-angiogenic drugs are active in SFT. PFS and overall response do not appear significantly lower than other reported series on the same disease. Furthermore, pazopanib is a drug already licensed in soft tissue sarcomas and these data suggest its activity also in this particular subtype of sarcomas.
No takes yet. Share an insight, caveat, or question.
Maruzzo et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: